Opioid growth factor (OGF) for hepatoblastoma: a novel non-toxic treatment

Invest New Drugs
August 2013
https://pubmed.ncbi.nlm.nih.gov/23275062/

Metabolic treatment of cancer: intermediate results of a prospective case series

Anticancer Res
February 2014
https://pubmed.ncbi.nlm.nih.gov/24511042/

Background: The combination of hydroxycitrate and lipoic acid has been demonstrated by several laboratories to be effective in reducing murine cancer growth.

Long-term remission of adenoid cystic tongue carcinoma with low dose naltrexone and vitamin D3--a case report

Oral Health Dent Manag
September 2014
http://oralhealth.ro/volumes/2014/volume-3/Paper662.pdf

Revisiting the ALA/N (alpha-lipoic acid/low-dose naltrexone) protocol for people with metastatic and nonmetastatic pancreatic cancer: a report of 3 new cases

Integr Cancer Ther
December 2009
https://pubmed.ncbi.nlm.nih.gov/20042414/

Inhibition of human colon cancer by intermittent opioid receptor blockade with naltrexone

Cancer Lett
29 March 1996
https://pubmed.ncbi.nlm.nih.gov/8620464/

Opioid antagonist modulation of murine neuroblastoma: a profile of cell proliferation and opioid peptides and receptors

Brain Res
20 February 1989
https://pubmed.ncbi.nlm.nih.gov/2540873/

Modulation of human neuroblastoma transplanted into nude mice by endogenous opioid systems

Life Sci
21 September 1987
https://pubmed.ncbi.nlm.nih.gov/3041143/

Duration of opiate receptor blockade determines tumorigenic response in mice with neuroblastoma: a role for endogenous opioid systems in cancer

Life Sci
23 July 1984
https://pubmed.ncbi.nlm.nih.gov/6087062/

Naltrexone modulates tumor response in mice with neuroblastoma

Science
12 August 1983
https://pubmed.ncbi.nlm.nih.gov/6867737/

Opioid antagonists inhibit the growth of metastatic murine neuroblastoma

Cancer Lett
November 1983
https://pubmed.ncbi.nlm.nih.gov/6640516/